Thermo Fisher Scientific (NYSE:TMO) Shares Gap Down – What’s Next?

Thermo Fisher Scientific Inc. (NYSE:TMO)’s stock price gapped down before the market opened on Wednesday. The stock had previously closed at $687.37, but opened at $665.00. Thermo Fisher Scientific shares last traded at $690.1890, with a volume of 732,999 shares traded.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher reported third-quarter revenue of $12.14 billion, up 9% year over year and above the approximately $11.95 billion consensus estimate. Adjusted EPS rose 15% to $6.68, beating expectations of $6.40, while organic revenue growth reached 6%. Thermo Fisher Scientific Reports Third Quarter 2026 Results
• Positive Sentiment: Improved margins and double-digit adjusted profit growth suggest operating leverage and resilient demand across the company’s life-science tools and services businesses. The quarter also extended Thermo Fisher’s record of earnings beats. Thermo Fisher posts higher third-quarter revenue and earnings as margins improve
• Neutral Sentiment: The broader bioprocessing market is expected to expand as biologics manufacturing, vaccine production, outsourcing, artificial intelligence and single-use systems gain adoption. This provides a favorable industry backdrop for Thermo Fisher, though the market reports are not company-specific financial guidance. Global Bioprocessing Reagent Market Report 2026
• Negative Sentiment: Despite the earnings and revenue beats, shares initially fell in premarket trading. The decline likely reflected high investor expectations following a strong run-up, as well as potential concerns about whether the results and outlook were strong enough to justify TMO’s premium valuation. TMO Q3 Earnings and Revenues Beat Estimates
• Negative Sentiment: Investors purchased 4,906 put options, 52% above typical put volume of 3,229 contracts. The activity signals increased near-term hedging or bearish speculation, although options flow alone does not establish a longer-term negative outlook.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research analyst reports. HSBC raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 1st. Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an “overweight” rating for the company. Royal Bank Of Canada set a $740.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, October 15th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $720.00 price target on shares of Thermo Fisher Scientific in a report on Friday, September 25th. Finally, Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $654.05.

Thermo Fisher Scientific Price Performance

The company’s 50-day simple moving average is $640.60 and its 200-day simple moving average is $551.25. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company has a market cap of $259.64 billion, a price-to-earnings ratio of 37.74, a P/E/G ratio of 2.83 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, beating the consensus estimate of $6.40 by $0.28. The business had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.79 earnings per share. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares in the company, valued at $13,927,815. The trade was a 1.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Shafer sold 25,500 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,768 shares of company stock worth $44,122,820 over the last three months. Insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TMO. Legacy Wealth Managment LLC ID grew its position in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares in the last quarter. Kilter Group LLC bought a new stake in shares of Thermo Fisher Scientific in the second quarter worth $25,000. Allied Private Wealth LLC bought a new stake in shares of Thermo Fisher Scientific in the second quarter worth $26,000. MBM Wealth Consultants LLC acquired a new stake in Thermo Fisher Scientific in the first quarter valued at $29,000. Finally, Pingora Partners LLC acquired a new stake in Thermo Fisher Scientific in the second quarter valued at $30,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.